The Ministry of Health proposes to include antimicrobials in the definition of “New Drug”, a separate license for the wholesale sale of drugs

Image for representation purposes. | Photo credit: File

The Union Health Ministry has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019 to include “antimicrobial agents” in the definition of “new drug” under Rule 2(1)(w)(v).

Antimicrobial resistance (AMR) is a major global public health concern and the proposed change was initiated in response to concerns about the granting of manufacturing licenses for antimicrobials without adequate regulatory scrutiny, including the requirement for studies such as bioavailability and bioequivalence and stability studies.

The proposed amendment seeks to bring antimicrobials into the regulatory framework applicable to new drugs under the new Medicines and Clinical Trials Rules, 2019. Accordingly, manufacturers would have to obtain permission from the central licensing authority before applying for a manufacturing license from the concerned state licensing authority. This is expected to strengthen central regulatory oversight and help ensure the quality, safety and efficacy of antimicrobials.

Meanwhile, the ministry also proposed amendments to the Drugs Rules, 1945 to introduce a separate application form (Form 19-BC) and license form (Form 20-BC) for the sale of bulk drugs (active or inactive bulk substances), different from the existing licensing provisions for formulations.

Currently, the joint license covers the wholesale sale of pharmaceutical forms as well as bulk drugs. The proposed amendment seeks to create a specialized licensing framework for bulk drugs that will allow for more targeted regulatory oversight of their wholesale sales and greater accountability in the pharmaceutical supply chain.

The proposal was approved by the Drugs Consultative Committee (DCC) at its 67th meeting held on 17 November 2025 and by the Drugs Technical Advisory Board (DTAB) at its 93rd meeting held on 16 February 2026.

Under the proposed framework, the license will capture the categories of bulk drugs handled by wholesalers, including those covered by the Narcotic and Psychotropic Substances (NDPS) Act 1985. The sale of bulk drugs will take place under the personal supervision of a competent person, thereby enhancing accountability in their distribution and handling.

“Once implemented, the proposed amendment will: provide better control over the sale of bulk drugs through wholesale, strengthen enforcement control in relation to antimicrobial resistance and the movement of NDPS drugs, and require wholesalers of bulk drugs to obtain a separate license to sell. Stakeholders and the public are invited to submit their objections and suggestions.”

Published – 19 Nov 2026 16:56 IST